Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Desmopressin acetate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Desmopressin tablets are round, white tablets. They contain the active ingredient desmopressin acetate hydrate. Desmopressin tablets are used for the treatment of:
Taking other medicines Please tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines, including medicines obtained without a prescription. This is especially important of the following substances as they may interact with your Desmopressin tablets:
110084
PACKAGE LEAFLET: INFORMATION FOR THE USER
Dosage Desmopressin tablets are taken by mouth. Always take Desmopressin exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Treatment of Diabetes Insipidus: The starting dose in adults and children is 100 micrograms, three times daily. The dose should then be adjusted according to the patient's response. For most patients, the adjusted dose is 100 to 200 micrograms, three times daily. Post-hypophysectomy polyuria/polydipsia: The dose of Desmopressin depends on the concentration of the urine. Primary nocturnal enuresis: The usual dose for children (from 5 years of age) and adults (up to 65 years of age) is 200 micrograms at bedtime. If necessary, your doctor may increase the dose to 400 micrograms. The need for continued treatment should be reassessed after 3 months by stopping treatment with Desmopressin for at least one week. If it appears that Desmopressin is not having an effect at low doses, your doctor may tell you not to take the tablets with food. If you take more Desmopressin than you should Go to the accident and emergency department at the nearest hospital straight away. Take the Desmopressin pack with you.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Desmopressin tablets can cause side effects, although not everybody gets them. All medicines can cause allergic reactions, although serious allergic reactions are very rare. Stop taking Desmopressin tablets and tell your doctor or go to the nearest hospital casualty department straight away if you experience any of the following:
Desmopressin Desmopressin tablets should be kept out of the sight and reach of children. Do not use Desmopressin after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Store below 25°C. Store in the original package. Keep the bottle tightly closed. Keep the bottle in the outer carton. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer needed. These measures will help to protect the environment. 6 Further information What Desmopressin tablets contain The active substance is desmopressin acetate hydrate. The other ingredients are: lactose monohydrate,
potato starch, povidone, magnesium stearate and colloidal anhydrous silica. What Desmopressin tablets look like and contents of the pack 30ml plastic bottles with a tamper-proof, twist-off cap and a silica gel desiccant insert. Each bottle contains either 30 or 90 tablets. The tablets are white, round and convex with break marks. Not all pack sizes may be marketed. Marketing Authorisation Holder Aspire Pharma Limited Unit 4, Rotherbrook Court Bedford Road Petersfield Hampshire, GU32 3QG United Kingdom Manufacturer Gebro Pharma GmbH, Bahnhofbichl 13, 6391 Fieberbrunn, Austria This leaflet was last revised in January 2021 8094717-04
Under licence from NTC S.r.l., Italy 1010046-P6.8
110084
3 How you take Desmopressin
Desmopressin acetate 100 microgram Tablet comes as tablet containing 100mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Desmopressin acetate 100 microgram Tablet is desmopressin acetate.
This leaflet reproduces the patient information leaflet approved for Desmopressin acetate 100 microgram Tablet, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Desmopressin acetate Tablets are indicated for:
• the treatment of vasopressin-sensitive cranial diabetes insipidus.
• the treatment of post-hypophysectomy polyuria/polydipsia.
• the treatment of primary nocturnal enuresis.
For oral use.
Treatment of Diabetes Insipidus:
Dosage is individual in diabetes insipidus but clinical experience has shown that the total daily dose normally lies in the range of 200micrograms to 1200micrograms. A suitable starting dose in adults and children is 100micrograms three times daily. This dosage regimen should then be adjusted in accordance with the patient's response. For the majority of patients, the maintenance dose is 100micrograms to 200micrograms three times daily.
Post-hypophysectomy polyuria/polydipsia:
The dose of Desmopressin acetate Tablets should be controlled by measurement of urine osmolality.
Primary nocturnal enuresis:
Children (from 5 years of age) and adults (up to 65 years of age) with normal urine concentrating ability who have primary nocturnal enuresis should take 200micorgrams at bedtime and only if needed should the dose be increased to 400micrograms.
The need for continued treatment should be reassessed after 3 months by means of a period of at least 1 week without Desmopressin acetate tablets.
Hypersensitivity to desmopressin or any of the excipients.
Cardiac insufficiency and other conditions requiring treatment with diuretic agents.
When used to control primary nocturnal enuresis Desmopressin acetate Tablets should only be used in patients with normal blood pressure.
Before prescribing Desmopressin acetate Tablets the diagnoses of psychogenic polydipsia and alcohol abuse should be excluded.
Desmopressin should not be prescribed to patients over the age of 65 for the treatment of primary nocturnal enuresis.
Hyponatraemia.
Syndrome of inappropriate secretion of antidiuretic hormone.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Care should be taken with patients who have reduced renal function and/or cardiovascular disease or cystic fibrosis. In chronic renal disease the antidiuretic effect of Desmopressin acetate Tablets would be less than normal.
When Desmopressin acetate Tablets are used for the treatment of enuresis, fluid intake must be limited from 1 hour before until 8 hours after administration.
Patients being treated for primary nocturnal enuresis should be warned to avoid ingesting water while swimming and to discontinue Desmopressin acetate Tablets during an episode of vomiting and/or diarrhoea until their fluid balance is once again normal.
Precautions to prevent fluid overload must be taken in:
- conditions characterised by fluid and/or electrolyte imbalance
- patients at risk for increased intracranial pressure
It is important to monitor body weight and blood pressure during treatment with desmopressin.
Substances which are known to induce SIADH e.g. tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine and carbamazepine, may cause an additive antidiuretic effect leading to an increased risk of water retention and/or hyponatraemia.
NSAIDs may induce water retention and/or hyponatraemia.
Concomitant treatment with loperamide may result in a 3-fold increase of desmopressin plasma concentrations, which may lead to an increased risk of water retention and/or hyponatraemia. Although not investigated, other drugs slowing transport might have the same effect.
A standardised 27% fat meal significantly decreased the absorption (rate and extent) of a 0.4mg dose of oral desmopressin. Although it did not significantly affect the pharmacodynamic effect (urine production and osmolality), there is the potential for this to occur at lower doses. If a diminution of effect is noted, then the effect of food should be considered before increasing the dose.
Pregnancy:
Data on a limited number (n=53) of exposed pregnancies in women with diabetes insipidus indicate rare cases of malformations in children treated during pregnancy. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.
Caution should be exercised when prescribing to pregnant women. Blood pressure monitoring is recommended due to the increased risk of pre-eclampsia.
Lactation:
Results from analyses of milk from nursing mothers receiving high dose desmopressin (300 micrograms intranasally) indicate that the amounts of desmopressin that may be transferred to the child are considerably less than the amounts required to influence diuresis.
None.
Gastrointestinal tract:
Stomach pain, nausea, abdominal cramps, vomiting
Nervous system disorders:
Headache
Very rare; emotional disturbance in children.
Skin/General:
Allergic skin reactions and more severe general allergic reactions
Treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/ risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme (www.mhra.gov.uk/yellowcard).
An overdose of Desmopressin acetate Tablets leads to a prolonged duration of action with an increased risk of water retention and/or hyponatraemia.
Treatment:
Although the treatment of hyponatraemia should be individualised, the following general recommendations can be given. Hyponatraemia is treated by discontinuing the desmopressin treatment, fluid restriction and symptomatic treatment if needed. Therefore, symptoms such as an increase in body weight, headache, nausea, abdominal cramps and in severe cases cerebral oedema, convulsions and coma may be expected.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Desmopressin acetate 100 microgram Tablet. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.